Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication
Open accessThe DOI matches its Crossref record; 62 of the 67 references it cites were found in a registry or an index.
Abstract
Deregulation of cyclin D1 occurs in numerous human cancers through mutations, alternative splicing, and gene amplification. Although cancer-derived cyclin D1 mutants are potent oncogenes in vitro and in vivo, the mechanisms whereby they contribute to neoplasia are poorly understood. We now provide evidence derived from both mouse models and human cancer-derived cells revealing that nuclear accumulation of catalytically active mutant cyclin D1/CDK4 complexes triggers DNA rereplication, resulting from Cdt1 stabilization, which in turn triggers the DNA damage checkpoint and p53-dependent apoptosis. Loss of p53 through mutations or targeted deletion results in increased genomic instability and neoplastic growth. Collectively, the data presented reveal mechanistic insights into how uncoupling of critical cell cycle regulatory events will perturb DNA replication fidelity, thereby contributing to neoplastic transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, certain cyclin D mutants or C-terminally truncated variants encoded by an alternatively spliced mRNA (D1b) that lacks the Thr-286 codon are retained in the nucleus during S phase and are proposed to confer a neo-oncogenic function that triggers DNA re-replication, aneuploidy, and tumorigenesis (59-61).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., & Bonner, W. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5858 · Cited by 5,438 · cited 2×
“previously by Rogakou et al. (1998). Soluble and chromatin frac-”
MethodSherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 2×
“…al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000; Hemmer et al. 2001; Ikeguchi et al. 2001; Jin et al. 2001); overexpression can result from gene amplification, chromosomal translocation, or protein stabilization (Sherr 1996).”
BackgroundCell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · cited 3×
“The deleterious effects of D1T286A-dependent DNA rereplication and genomic instability is initially opposed by p53-dependent apoptosis that occurs in response to DNA breaks, perturbations in DNA replication, and oncogene activation (Kastan and Bartek 2004).”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 3×
“…remains controversial, activation of the DNA damage checkpoint signaling pathway in preneoplastic tissue is consistent with the former (Bartkova et al. 2005; Gorgoulis et al. 2005) and suggests that initial “hits” trigger DNA damage and p53-dependent apoptosis to counter accumulation…”
BackgroundGlycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 1×
“Ras also contributes to the accumulation of the cyclin D1 protein, via a pathway involving PI3K and Akt, which attenuates the GSK3 kinase (Franke et al. 1995, 1997); GSK3 -dependent phosphorylation of cyclin D1 on Thr286 promotes cyclin D1 proteolysis (Diehl et al. 1998).”
BackgroundSelf-citationDNA Replication in Eukaryotic Cells
Bell, S. P., & Dutta, A. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135425 · Cited by 2,060 · cited 2×
“During G1 phase, DNA replication origins are established via loading of ORC (origin recognition complex) followed by Cdt1/CDC6-dependent loading of the replicative MCM helicase (Bell and Dutta 2002).”
BackgroundActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · cited 3×
“Recent work revealed induction of DNA damage in premalignant tissue (Bartkova et al. 2005; Gorgoulis et al. 2005), suggesting a mechanism whereby oncogenic stress in nonmalignant cells may provide selective pressure to delete p53 and promote tumorigenesis.”
BackgroundFranke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006 · cited 1×
“Ras also contributes to the accumulation of the cyclin D1 protein, via a pathway involving PI3K and Akt, which attenuates the GSK3 kinase (Franke et al. 1995, 1997); GSK3 -dependent phosphorylation of cyclin D1 on Thr286 promotes cyclin D1 proteolysis (Diehl et al. 1998).”
BackgroundOncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“Recent work has correlated oncogene-induced senescence with induction of the DNA damage checkpoint in solid tumors (Bartkova et al. 2006; Di Micco et al. 2006).”
BackgroundOncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821 · cited 1×
“Recent work has correlated oncogene-induced senescence with induction of the DNA damage checkpoint in solid tumors (Bartkova et al. 2006; Di Micco et al. 2006).”
BackgroundDirect Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate
Franke, T. F., Kaplan, D. R., Cantley, L. C., & Toker, A. (1997) · Science · doi:10.1126/science.275.5300.665 · Cited by 1,460 · cited 1×
“Ras also contributes to the accumulation of the cyclin D1 protein, via a pathway involving PI3K and Akt, which attenuates the GSK3 kinase (Franke et al. 1995, 1997); GSK3 -dependent phosphorylation of cyclin D1 on Thr286 promotes cyclin D1 proteolysis (Diehl et al. 1998).”
BackgroundHerman, J. G., Merlo, A. U., Mao, L., Lapidus, R. G., Issa, J. J., Davidson, N. E., Sidransky, D., & Baylin, S. B. (1995) · PubMed · Cited by 1,341
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Ras activates canonical MAP kinase signaling (RAF–MEK–ERK); activation of this pathway is both necessary and sufficient for cyclin D1 expression and association with CDK4 (Albanese et al. 1995; Lavoie et al. 1996; Aktas et al. 1997; Cheng et al. 1998).”
BackgroundDistinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092 · cited 1×
“The inability of CDK4K35M to attenuate Cdt1 loss does not reflect cell cycle effects, as CDK4K35M does not elicit cell cycle arrest (van den Heuvel and Harlow 1993).”
BackgroundTransforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803 · cited 1×
“Ras activates canonical MAP kinase signaling (RAF–MEK–ERK); activation of this pathway is both necessary and sufficient for cyclin D1 expression and association with CDK4 (Albanese et al. 1995; Lavoie et al. 1996; Aktas et al. 1997; Cheng et al. 1998).”
BackgroundGillett, C., Fantl, V., Smith, D., Fisher, C., Bartek, J. J., Dickson, C., Barnes, D. M., & Peters, G. (1994) · PubMed · Cited by 759
Rajagopalan, H., & Lengauer, C. (2004) · Nature · doi:10.1038/nature03099 · Cited by 725
Tumor surveillance via the ARF–p53 pathway
Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.19.2984 · Cited by 717 · cited 2×
“p53 is activated by numerous pathways, including inappropriate expression of oncogenes and DNA damage (Sherr 1998).”
BackgroundDeregulated cyclin E induces chromosome instability
Spruck, C. H., Won, K.-A., & Reed, S. I. (1999) · Nature · doi:10.1038/45836 · Cited by 692 · cited 3×
“The ability of nuclear D1T286A, but not wild-type cyclin D1, to inhibit Cdt1 proteolysis and promote rereplication is consistent with previously published work revealing that overexpressed wild-type cyclin D1 does not elicit a DNA damage response (Spruck et al. 1999; Tort et al. 2006).”
BackgroundJin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632 · cited 2×
“A smaller subset exhibited reduced Cdt2 message, the specificity component that directs Cul4 to Cdt1 (Higa et al. 2006; Jin et al. 2006; Sansam et al. 2006), as well as Cul4 (e.g., tumors 634, 775).”
BackgroundAlt, J. R., Cleveland, J. L., Hannink, M., & Diehl, J. A. (2000) · Genes & Development · doi:10.1101/gad.854900 · Cited by 535 · cited 6×
“Phosphorylation of cyclin D1 on Thr286 at the G1/S-phase boundary promotes CRM1-dependent nuclear export (Alt et al. 2000).”
BackgroundSelf-citationCyclin D1 protein expression and function in human breast cancer
Bartkova, J., Lukas, J., Müller, H., Lützhøt, D., Strauss, M., & Bartek, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570311 · Cited by 509 · cited 1×
“Cyclin D1 overexpression occurs in carcinomas of the esophagus, head and neck, breast, and colon, as well as certain B-cell lymphomas (Bartkova et al. 1994a,b, 1995; Gillett et al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000;…”
BackgroundCheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496 · cited 1×
“Ras activates canonical MAP kinase signaling (RAF–MEK–ERK); activation of this pathway is both necessary and sufficient for cyclin D1 expression and association with CDK4 (Albanese et al. 1995; Lavoie et al. 1996; Aktas et al. 1997; Cheng et al. 1998).”
BackgroundBodrug, S. E., Warner, B. J., Bath, M. L., Lindeman, G. J., Harris, A. W., & Adams, J. M. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06488.x · Cited by 441 · cited 2×
“…of cyclin D1 is considered the initial genetic trigger in mantle cell lymphoma, targeted expression of wildtype cyclin D1 in lymphoid cells does not result in a tumor-prone phenotype (Bodrug et al. 1994; Lovec et al. 1994), thereby challenging the notion that cyclin D1 is an oncogene.”
BackgroundRequirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429 · cited 1×
“Recent data reveal that formation of active cyclin D1/CDK4 kinase is critical for Neu-dependent tumorigenesis (Landis et al. 2006; Yu et al. 2006).”
BackgroundHiga, L. A., Wu, M., Ye, T., Kobayashi, R., Sun, H., & Zhang, H. (2006) · Nature Cell Biology · doi:10.1038/ncb1490 · Cited by 413 · cited 1×
“A smaller subset exhibited reduced Cdt2 message, the specificity component that directs Cul4 to Cdt1 (Higa et al. 2006; Jin et al. 2006; Sansam et al. 2006), as well as Cul4 (e.g., tumors 634, 775).”
BackgroundCyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.
Lovec, H., Grzeschiczek, A., Kowalski, M. B., & Möröy, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06655.x · Cited by 410 · cited 2×
“…of cyclin D1 is considered the initial genetic trigger in mantle cell lymphoma, targeted expression of wildtype cyclin D1 in lymphoid cells does not result in a tumor-prone phenotype (Bodrug et al. 1994; Lovec et al. 1994), thereby challenging the notion that cyclin D1 is an oncogene.”
BackgroundAktas, H., Cai, H., & Cooper, G. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3850 · Cited by 410 · cited 1×
“Ras activates canonical MAP kinase signaling (RAF–MEK–ERK); activation of this pathway is both necessary and sufficient for cyclin D1 expression and association with CDK4 (Albanese et al. 1995; Lavoie et al. 1996; Aktas et al. 1997; Cheng et al. 1998).”
BackgroundA p53-Dependent Checkpoint Pathway Prevents Rereplication
Vaziri, C., Saxena, S., Jeon, Y., Lee, C., Murata, K., Machida, Y., Wagle, N., Hwang, D. S., & Dutta, A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00099-6 · Cited by 393 · cited 5×
“Second, rereplication results in DNA damage (Vaziri et al. 2003; Davidson et al. 2006) that in turn contributes to an increased frequency of oncogenic mutations and tumor heterogeneity (e.g., genomic instability).”
BackgroundMethodInfluentialTwo E3 ubiquitin ligases, SCF‐Skp2 and DDB1‐Cul4, target human Cdt1 for proteolysis
Nishitani, H., Sugimoto, N., Roukos, V., Nakanishi, Y., Saijo, M., Obuse, C., Tsurimoto, T., Nakayama, K. I., Nakayama, K., Fujita, M., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601002 · Cited by 392 · cited 4×
“Accumulation of Cdt1 can be regulated by both the SCF- and Cul4-based E3 ubiquitin ligases (Nishitani et al. 2006).”
BackgroundInfluentialPhosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex
Lin, D. I., Barbash, O., Kumar, K. G. S., Weber, J. D., Harper, J. W., Klein-Szanto, A. J. P., Rustgi, A., Fuchs, S. Y., & Diehl, J. A. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.09.007 · Cited by 349 · cited 3×
“2000) and cyclin D1 proteolysis, which occurs in the cytoplasm (Lin et al. 2006).”
BackgroundSelf-citationCyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329 · cited 1×
“Recent data reveal that formation of active cyclin D1/CDK4 kinase is critical for Neu-dependent tumorigenesis (Landis et al. 2006; Yu et al. 2006).”
BackgroundAn alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.
Lu, F., Gladden, A. B., & Diehl, J. A. (2003) · PubMed · Cited by 284
Self-citationBani-Hani, K., Martin, I. G., Hardie, L. J., Mapstone, N., Briggs, J. A., Forman, D., & Wild, C. P. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1316 · Cited by 247
Barnes, D. M., & Gillett, C. E. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006103831990 · Cited by 243 · cited 2×
“…head and neck, breast, and colon, as well as certain B-cell lymphomas (Bartkova et al. 1994a,b, 1995; Gillett et al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000; Hemmer et al. 2001; Ikeguchi et al. 2001; Jin et al.…”
BackgroundAbnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer.
Bártková, J., Lukáš, J., Müller, H., von Strauss, M., Gusterson, B. A., & Bartek, J. J. (1995) · PubMed · Cited by 236
Solomon, D. A., Wang, Y., Fox, S. R., Lambeck, T. C., Giesting, S., Lan, Z., Senderowicz, A. M., & Knudsen, E. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303969200 · Cited by 218 · cited 1×
“Cyclin D1 is subject to point mutations, in-frame deletions, and cancer-specific alternative splicing in various human malignancies (Lu et al. 2003; Moreno-Bueno et al. 2003; Solomon et al. 2003; Benzeno et al. 2006).”
BackgroundCyclin-dependent Kinases Phosphorylate Human Cdt1 and Induce Its Degradation
Liu, E., Li, X., Yan, F., Zhao, Q., & Wu, X. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300549200 · Cited by 188 · cited 2×
“Finally, CDK2 activity triggers Cdt1 proteolysis, through the Skp2 E3 ligase (Liu et al. 2004; Sugimoto et al. 2004; Takeda et al. 2005; Hu and Xiong 2006).”
BackgroundSugimoto, N., Tatsumi, Y., Tsurumi, T., Matsukage, A., Kiyono, T., Nishitani, H., & Fujita, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313175200 · Cited by 177 · cited 1×
“Finally, CDK2 activity triggers Cdt1 proteolysis, through the Skp2 E3 ligase (Liu et al. 2004; Sugimoto et al. 2004; Takeda et al. 2005; Hu and Xiong 2006).”
BackgroundDTL/CDT2 is essential for both CDT1 regulation and the early G2/M checkpoint
Sansam, C. L., Shepard, J. L., Lai, K., Ianari, A., Danielian, P. S., Amsterdam, A., Hopkins, N., & Lees, J. A. (2006) · Genes & Development · doi:10.1101/gad.1482106 · Cited by 171 · cited 2×
“A smaller subset exhibited reduced Cdt2 message, the specificity component that directs Cul4 to Cdt1 (Higa et al. 2006; Jin et al. 2006; Sansam et al. 2006), as well as Cul4 (e.g., tumors 634, 775).”
BackgroundIdentification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1
Benzeno, S., Lu, F., Guo, M., Barbash, O., Zhang, F., Herman, J. G., Klein, P. S., Rustgi, A. K., & Diehl, J. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209644 · Cited by 167 · cited 9×
“Constitutively nuclear cyclin D1 mutants are found in carcinomas of the esophagus, and induce cell transformation in vitro (Benzeno et al. 2006) and promote tumorigenesis in transgenic mice (Gladden et al. 2006).”
BackgroundSelf-citationThe PRAD‐1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas
Bártková, J., Lukas, J., Strauss, M., & Bártek, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580420 · Cited by 163 · cited 1×
“Cyclin D1 overexpression occurs in carcinomas of the esophagus, head and neck, breast, and colon, as well as certain B-cell lymphomas (Bartkova et al. 1994a,b, 1995; Gillett et al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000;…”
BackgroundHow do small GTPase signal transduction pathways regulate cell cycle entry?
Marshall, C. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00044-7 · Cited by 162 · cited 5×
“Cyclin D1 gene expression depends on activation of the small GTP-binding protein, Ras (Marshall 1999).”
BackgroundInfluentialThe activities of cyclin D1 that drive tumorigenesis
Ewen, M. E., & Lamb, J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.02.005 · Cited by 162 · cited 1×
“Numerous studies have provided links between cyclin D1 and transcriptional regulators and histone-modifying enzymes (Ewen and Lamb 2004).”
BackgroundDavidson, I. F., Li, A., & Blow, J. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.09.010 · Cited by 138 · cited 4×
“How does rereplication trigger DSBs? Recent work has revealed that small DNA fragments are generated as a consequence of replication fork collision during rereplication (Davidson et al. 2006).”
BackgroundInfluentialHibberts, N. A., Simpson, D. J. W., Bicknell, J., Broome, J. C., Hoban, P. R., Clayton, R. N., & Farrell, W. E. (1999) · PubMed · Cited by 137
Location, location, location: The role of cyclin D1 nuclear localization in cancer
Gladden, A. B., & Diehl, J. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20613 · Cited by 136 · cited 1×
“Cyclin D expression, accumulation, and its ability to associate with catalytic partners CDK4/6 are regulated by mitogenic signaling, allowing D cyclins to serve as mediators of growth factor signaling and cell cycle progression (Gladden and Diehl 2005).”
BackgroundSelf-citationCyclin D1 gene (CCND1) mutations in endometrial cancer
Moreno‐Bueno, G., Rodríguez, S., Sánchez‐Estévez, C., Hardisson, D., Sarrió, D., Prat, J., Cigudosa, J. C., Matías‐Guiu, X., & Palacios, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206868 · Cited by 136 · cited 1×
“Cyclin D1 is subject to point mutations, in-frame deletions, and cancer-specific alternative splicing in various human malignancies (Lu et al. 2003; Moreno-Bueno et al. 2003; Solomon et al. 2003; Benzeno et al. 2006).”
BackgroundExpression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma
Gladden, A. B., Woolery, R., Aggarwal, P., Wasik, M. A., & Diehl, J. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209147 · Cited by 131 · cited 12×
“Constitutively nuclear cyclin D1 mutants are found in carcinomas of the esophagus, and induce cell transformation in vitro (Benzeno et al. 2006) and promote tumorigenesis in transgenic mice (Gladden et al. 2006).”
BackgroundMethodResultSelf-citationRibosomal Stress Couples the Unfolded Protein Response to p53-dependent Cell Cycle Arrest
Zhang, F., Hamanaka, R. B., Bobrovnikova-Marjon, E., Gordan, J. D., Dai, M.-S., Lu, H., Simon, M. C., & Diehl, J. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604674200 · Cited by 119 · cited 2×
“For BrdU-PI analysis, cells were harvested, fixed, and stained as described previously (Zhang et al. 2006).”
BackgroundMethodSelf-citationHu, J., & Xiong, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500464200 · Cited by 118 · cited 1×
“Finally, CDK2 activity triggers Cdt1 proteolysis, through the Skp2 E3 ligase (Liu et al. 2004; Sugimoto et al. 2004; Takeda et al. 2005; Hu and Xiong 2006).”
BackgroundA mouse model for cyclin E-dependent genetic instability and tumorigenesis
Loeb, K. R., Kostner, H., Firpo, E. J., Norwood, T. H., Tsuchiya, K. D., Clurman, B. E., & Roberts, J. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.010 · Cited by 117 · cited 2×
“Proteasome-resistant cyclin E can also trigger genomic instability (Spruck et al. 1999; Loeb et al. 2005; Tort et al. 2006).”
BackgroundTakeda, D. Y., Parvin, J. D., & Dutta, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501208200 · Cited by 115 · cited 1×
“Finally, CDK2 activity triggers Cdt1 proteolysis, through the Skp2 E3 ligase (Liu et al. 2004; Sugimoto et al. 2004; Takeda et al. 2005; Hu and Xiong 2006).”
BackgroundJin, M., Inoue, S., Umemura, T., Moriya, J., ARAKAWA, M., Nagashima, K., & Kato, H. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00225-2 · Cited by 112 · cited 2×
“…al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000; Hemmer et al. 2001; Ikeguchi et al. 2001; Jin et al. 2001); overexpression can result from gene amplification, chromosomal translocation, or protein stabilization (Sherr 1996).”
BackgroundOpitz, O. G., Suliman, Y., Hahn, W. C., Harada, H., Blum, H. E., & Rustgi, A. K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11909 · Cited by 99 · cited 1×
“While very little rereplication could be detected in NIH3T3 cells, coexpression of dominant-negative p53V143A (Opitz et al. 2001) permitted a significant accumulation of cells with >4N DNA content (Fig.”
BackgroundSelf-citationImmunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development
Lieubeau, B., Heymann, M., Henry, F., Barbieux, I., Méflah, K., & Gr�goire, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990517)81:4<616::aid-ijc18>3.0.co;2-s · Cited by 85 · cited 2×
“…as certain B-cell lymphomas (Bartkova et al. 1994a,b, 1995; Gillett et al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000; Hemmer et al. 2001; Ikeguchi et al. 2001; Jin et al. 2001); overexpression can result from gene…”
BackgroundGladden, A. B., & Diehl, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212088200 · Cited by 82 · cited 4×
“Soluble and chromatin fractions were prepared as described previously (Gladden and Diehl 2003).”
BackgroundMethodSelf-citationOpitz, O. G., Suliman, Y., Hahn, W. C., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200111909 · Cited by 79
Deletion of 11q23 and Cyclin D1 Overexpression Are Frequent Aberrations in Parathyroid Adenomas
Hemmer, S., Wasenius, V.-M., Haglund, C. H., Zhu, Y., Knuutila, S., Franssila, K., & Joensuu, H. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64086-2 · Cited by 76 · cited 2×
“…1994a,b, 1995; Gillett et al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000; Hemmer et al. 2001; Ikeguchi et al. 2001; Jin et al. 2001); overexpression can result from gene amplification, chromosomal translocation, or protein…”
BackgroundTort, F., Bartkova, J., Sehested, M., Ørntoft, T., Lukas, J., & Bartek, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2178 · Cited by 67 · cited 3×
“The ability of nuclear D1T286A, but not wild-type cyclin D1, to inhibit Cdt1 proteolysis and promote rereplication is consistent with previously published work revealing that overexpressed wild-type cyclin D1 does not elicit a DNA damage response (Spruck et al. 1999; Tort et al. 2006).”
BackgroundIkeguchi, M., Sakatani, T., Ueta, T., & Kaibara, N. (2001) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320100265 · Cited by 46 · cited 2×
“…et al. 1994; Herman et al. 1995; Barnes and Gillett 1998; Hibberts et al. 1999; Hosokawa et al. 1999; BaniHani et al. 2000; Hemmer et al. 2001; Ikeguchi et al. 2001; Jin et al. 2001); overexpression can result from gene amplification, chromosomal translocation, or protein stabilization (Sherr…”
BackgroundDNA Damage and Tumor Surveillance: One Trigger for Two Pathways
Höglund, P. (2006) · Science s STKE · doi:10.1126/stke.3172006pe2 · Cited by 27 · cited 1×
“Genomic integrity is monitored by checkpoints designed to trigger cell cycle arrest or apoptosis (Kastan and Bartek 2004; Hoglund 2006).”
Background
Cited by
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
“, perhaps acting as a 'safety net' for rapidly proliferating cells, but sustained cyclin D1–CDK4 activity following DNA damage leads to the inappropriate re-replication of DNA and chromosomal damag”
BackgroundGaillard, H., García-Muse, T., & Aguilera, A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3916 · Cited by 1,089
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
“Investigation of the mechanisms that underscore nuclear cyclin D1-dependent neoplastic growth revealed overexpression of the constitutively nuclear and stable cyclin D1 (T286A), but not wild-type cyclin D1, which promotes stabilization and mis-expression of the DNA replication licensing factor Cdt1, which then trigger…”
BackgroundSelf-citationNon-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
Metadata
- Authors
- Aggarwal, P., Lessie, M. D., Lin, D. I., Pontano, L., Gladden, A. B., Nuskey, B., Goradia, A., Wasik, M. A., Klein-Szanto, A. J. P., Rustgi, A. K., Bassing, C. H., & Diehl, J. A.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- ORCID
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2007-11-15
- Volume
- 21
- Issue
- 22
- Pages
- 2908-2922
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC2049193
- OpenAlex
- W2112318168
- Cited by
- 132
- References
- 67
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 4 · 2020: 8 · 2019: 6 · 2018: 4 · 2017: 8 · 2016: 8 · 2015: 12 · 2014: 10 · 2013: 11 · 2012: 9
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA098101)
- National Cancer Institute (P01CA098101, R01CA093237, CA 93237)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- cyclin D1, Cdt1, CUL4, DNA re-replication, p53, DNA damage checkpoint, apoptosis, genomic instability, oncogenic transformation, S phase, DNA replication fidelity
- MeSH terms
- Animals, Cell Nucleus, Cells, Cultured, DNA, DNA Replication, DNA-Binding Proteins, DNA, Neoplasm, HeLa Cells, Humans, Hydrolysis, Lipopolysaccharides, Mice, Transgenic, Mutation, Osteosarcoma, Spleen, Tumor Suppressor Protein p53, S Phase, Cell Cycle Proteins, Cyclin D1, NIH 3T3 Cells, Cullin Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.